Short Interest in Aurinia Pharmaceuticals Inc. (AUPH) Declines By 26.9%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 724,217 shares, a decline of 26.9% from the September 15th total of 990,125 shares. Based on an average daily trading volume, of 3,413,232 shares, the short-interest ratio is presently 0.2 days. Approximately 4.1% of the shares of the company are sold short.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.16 on Friday. The stock has a 50 day moving average price of $2.77 and a 200-day moving average price of $2.83. Aurinia Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $5.69. The firm’s market cap is $146.79 million.
Several research firms have commented on AUPH. Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Saturday, October 8th. FBR & Co reaffirmed an “outperform” rating and set a $9.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 5th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, October 3rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $7.75.
Several large investors have recently bought and sold shares of the stock. Lombard Odier Asset Management USA Corp raised its stake in Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock worth $283,000 after buying an additional 2,813 shares during the period. Creative Planning bought a new stake in Aurinia Pharmaceuticals during the third quarter worth about $181,000. Finally, Abingworth LLP raised its stake in Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock worth $1,388,000 after buying an additional 423,729 shares during the period. Institutional investors and hedge funds own 20.04% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.